Stock Day Media: Acasti Pharma Discusses Positive Clinical Study Results for GTX-101 and GTX-102 and Upcoming Phase 3 Study for GTX-104 with The Stock Day Podcast

Phoenix, Arizona--(Newsfile Corp. - January 17, 2023) - The Stock Day Podcast welcomed Acasti Pharma, Inc. (NASDAQ: ACST), a late-stage specialty pharma company with drug delivery technologies and drug

Related Keywords

Phoenix ,Arizona ,United States ,Canada ,America ,Canadian ,Robert Blum ,Jan Dalvise ,Everett Jolly ,Arizona Newsfile Corp ,Nasdaq ,Exchange Commission ,Acasti Pharma Inc ,Lytham Partners ,Securities Exchange ,Regulation Services Provider ,Stock Day Podcast ,Acasti Pharma ,Jand Alvise ,Stock Day ,Subarachnoid Hemorrhage ,Stock Day Media ,Orphan Drug Designation ,Securities Litigation Reform Act ,Securities Act ,Securities Exchange Act ,Stock ,Media ,Ancasti ,Dharma ,Iscusses ,Positive ,Linical ,Study ,Results ,Pcoming ,Hase ,Odcast ,